Humachag, Jea G.
HRN: 05-93-26 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/29/2024
CEFTRIAXONE 1G (VIAL)
02/29/2024
03/07/2024
IV
1g
Q12
Lacerated Wound
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes